Effect of liver function on clinical outcomes in patients with unresectable hepatocellular carcinoma treated with first-line atezolizumab-bevacizumab: an Asia-Pacific multicenter retrospective analysis.
In multivariate analyses, CP class independently predicted PFS and OS, while ALBI predicted OS, which highlights the need to assess liver function when selecting systemic therapy and support further studies, including patients with impaired liver function.